Non-response to colchicine in FMF - Definition, causes and suggested solutions

Clinical and Experimental Rheumatology

Volumn 26, Issue 4 SUPPL. 50, 2008, Pages

  Ben Chetrit, Eldad ^a,b   Ozdogan, Huri ^a,c  

^a Department of Medicine ^*

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Colchicine; Drug resistance; FMF

Indexed keywords

ACETYLSALICYLIC ACID; COLCHICINE; INFLIXIMAB; INTERLEUKIN 1BETA ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; EDITORIAL; FAMILIAL MEDITERRANEAN FEVER; HUMAN; PRIORITY JOURNAL; RETREATMENT; TREATMENT FAILURE;

CLINICAL TRIALS AS TOPIC; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; GOUT SUPPRESSANTS; HUMANS; TREATMENT FAILURE;

EID: 55049131412     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. TUFAN A, BABAOGLU MO, AKDOGAN A et al.: Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 1540-4.
2. CERQUAGLIA C, DIACO M. NUCERA G, LA REGINA M, MONTALTO M, MANNA R: Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: An update. Curr Drug Targets Inflamm Allergy 2005; 4: 117-24.
3. SEYAHI E, OZDOGAN H, MASATLIOGLU S, YAZICI H: Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine-resistant patient. Clin Exp Rheumatol 2002; 20 (Suppl. 26): S43-4.
4. SEYAHI E, OZDOGAN H, CELIK S et al.: Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents. Clin Exp Rheumotol 2006: 24 (Suppl. 42): S99-103.
5. OZGOCMEN S, OZÇAKAR L, ARDICOGLU O, KOCAKOC E, KAYA A, KIRIS A: Familial Mediterranean fever responds well to infliximab: Single case experience. Clin Rheumatol 2006; 25: 83-7.
6. ROLDAN R, RUIZ AM, MIRANDA MD, COLLANTES E: Anakinra: New therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine, June 7, 2008 [E-pub ahead of print].
7. HALUSHKA MK, WALKER LP, HALUSHKA PV: Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
8. LIDAR M, SCHERRMANN JM, SHINAR Y et al.: Colchicine non-responsiveness in familial Mediterranean fever: Clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33: 273-82.
9. BEN-CHETRIT E, LEVY M: Familial Mediterranean fever. Lancet
10. NIEL E, SCHERRMANN JM: Colchicine today. Joint Bone Spine 2006; 73: 672-8.
11. AMERICAN COLLEGE OF RHEUMATOLOGY SUB-COMMITTEE ON RHEUMATOID ARTHRITIS GUIDELINES: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
12. BEN-CHETRIT E, LEVY M: Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses 1998; 51: 377-80.
13. MIZUTANI T, MASUDA M, NAKAI E et al.: Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008; 9: 167-74.
14. GALETIN A, ITO K, HALLIFAX D, HOUSTON JB: CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314: 180-90.